Avantor, Inc. Stock 12‑Month Price Target Raised to $15.04, Implies 2% Downside

Avantor, Inc.'s average stock price target increased from $14.85 to $15.04, with estimates ranging from $12 to $19. This implies a 2% downside from the Oct. 8 closing price. The consensus rating remains 'Hold' among 19 analysts, with 2 Buys, 15 Holds, and 2 Sells.

Original reporting
Published Oct 9, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avantor, Inc. Stock 12‑Month Price Target Raised to $15.04, Implies 2% Downside — source image
Decision brief

The 30-second read

$AVTRNeutralLow
01

Why it matters

The price‑target adjustment reflects analysts' modest optimism but still signals limited upside.

02

Market read

Analyst target change provides a small informational edge but is unlikely to drive significant price movement.

03

What to watch

Potential upcoming product launches or contract wins not yet reflected in analyst models could change the outlook.

Relevance 5/10Novelty 5/10Timing: today

Background

Avantor is a global supplier of chemicals and services to the life‑sciences and advanced‑technology markets.

Company-level read

Ticker impact

$AVTRNeutralMedium confidence
Context

Analysts raised Avantor's average price target to $15.04, implying ~2% downside from the current price.

Expected impact

potential slight downside as the market prices in the modest target raise

Evidence & confidence

Target raise is small and still below current price, likely leading to limited buying interest and modest pressure.

Market effects

Minimal impact on the life‑sciences sector; price‑target updates are routine.

Limited to US investors tracking Avantor; no broader regional effect.

Low; the news does not affect global markets.

Counterpoint

Some traders may view the target raise as a buying opportunity if they believe the market overreacted to the implied downside.

Key entities

  • Avantor, Inc.

    US‑listed life‑sciences chemicals supplier.

Related articles

$AVTRMedAI 8/10

Avantor Inc (AVTR) Q3 2026 Earnings Call Highlights: Return to Organic Growth, Raised

Avantor Inc (AVTR) reported Q3 2026 earnings, highlighting organic growth and raised guidance. CEO Emmanuel Ligner expressed confidence in 2027, citing strong momentum. CFO Todd Garner forecasted Q4 revenue growth of 2.5% to 4.5%, with VWR growing mid-single-digits. AI is seen as a potential tailwind. Margins faced pressure from mix and inflation, but EBITDA margin expansion is expected to continue. Investments in facilities and AI tools are ongoing, with returns anticipated over time.

$AVTRHighAI 8/10

What Avantor (AVTR) Said on Its Q3 Earnings Call

Avantor (AVTR) reported Q3 revenue of $465M for its Bioscience & Medtech Products segment, up 3.6% organically. Adjusted operating income was $123M with a 26.6% margin. The company raised its 2026 organic revenue growth outlook to 0.75-1.25% and increased its adjusted EPS and free cash flow projections. Avantor aims to reduce net leverage below 3x by year-end.

$AVTRHighAI 8/10

Avantor (AVTR) Q3 2026 Earnings Call Transcript

Avantor (AVTR) reported Q3 2026 earnings, exceeding expectations with $1.698B revenue (5.2% organic growth) and $0.22 adjusted EPS. VWR and BMP segments showed strong performance, driving growth. The company raised full-year guidance and aims to reduce leverage below 3x by year-end. Revival initiatives are improving execution and end-market demand.